146 related articles for article (PubMed ID: 10575334)
1. In long-term smokers and former smokers the bronchodilator response is not related to the fall in FEV.
Stănescu D; Veriter C; Sanna A
Respiration; 1999; 66(6):501-5. PubMed ID: 10575334
[TBL] [Abstract][Full Text] [Related]
2. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
Scanlon PD; Connett JE; Waller LA; Altose MD; Bailey WC; Buist AS; Tashkin DP;
Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):381-90. PubMed ID: 10673175
[TBL] [Abstract][Full Text] [Related]
3. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up.
Stănescu D; Sanna A; Veriter C; Robert A
Chest; 1998 Aug; 114(2):416-25. PubMed ID: 9726724
[TBL] [Abstract][Full Text] [Related]
4. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
Anthonisen NR; Connett JE; Kiley JP; Altose MD; Bailey WC; Buist AS; Conway WA; Enright PL; Kanner RE; O'Hara P
JAMA; 1994 Nov; 272(19):1497-505. PubMed ID: 7966841
[TBL] [Abstract][Full Text] [Related]
5. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
6. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.
Soriano JB; Sin DD; Zhang X; Camp PG; Anderson JA; Anthonisen NR; Buist AS; Burge PS; Calverley PM; Connett JE; Petersson S; Postma DS; Szafranski W; Vestbo J
Chest; 2007 Mar; 131(3):682-689. PubMed ID: 17356080
[TBL] [Abstract][Full Text] [Related]
7. The use of statins and lung function in current and former smokers.
Keddissi JI; Younis WG; Chbeir EA; Daher NN; Dernaika TA; Kinasewitz GT
Chest; 2007 Dec; 132(6):1764-71. PubMed ID: 17908708
[TBL] [Abstract][Full Text] [Related]
8. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
9. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.
Kanner RE; Anthonisen NR; Connett JE;
Am J Respir Crit Care Med; 2001 Aug; 164(3):358-64. PubMed ID: 11500333
[TBL] [Abstract][Full Text] [Related]
10. Bronchodilator response in the lung health study over 11 yrs.
Anthonisen NR; Lindgren PG; Tashkin DP; Kanner RE; Scanlon PD; Connett JE;
Eur Respir J; 2005 Jul; 26(1):45-51. PubMed ID: 15994388
[TBL] [Abstract][Full Text] [Related]
11. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
13. Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?
Rahman I; Swarska E; Henry M; Stolk J; MacNee W
Thorax; 2000 Mar; 55(3):189-93. PubMed ID: 10679536
[TBL] [Abstract][Full Text] [Related]
14. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers.
Makris D; Moschandreas J; Damianaki A; Ntaoukakis E; Siafakas NM; Milic Emili J; Tzanakis N
Respir Med; 2007 Jun; 101(6):1305-12. PubMed ID: 17112715
[TBL] [Abstract][Full Text] [Related]
15. Kurtosis and skewness of density histograms on inspiratory and expiratory CT scans in smokers.
Yamashiro T; Matsuoka S; Estépar RS; Bartholmai BJ; Diaz A; Ross JC; Murayama S; Silverman EK; Hatabu H; Washko GR
COPD; 2011 Feb; 8(1):13-20. PubMed ID: 21299474
[TBL] [Abstract][Full Text] [Related]
16. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity.
Chen CZ; Ou CY; Wang WL; Lee CH; Lin CC; Chang HY; Hsiue TR
COPD; 2012 Jun; 9(3):276-80. PubMed ID: 22360379
[TBL] [Abstract][Full Text] [Related]
17. Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease.
Lee JS; Huh JW; Chae EJ; Seo JB; Ra SW; Lee JH; Kim EK; Lee YK; Kim TH; Kim WJ; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Sheen SS; Oh YM; Lee SD
Clin Physiol Funct Imaging; 2012 Jan; 32(1):12-8. PubMed ID: 22152074
[TBL] [Abstract][Full Text] [Related]
18. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study.
Garcia-Aymerich J; Lange P; Benet M; Schnohr P; Antó JM
Am J Respir Crit Care Med; 2007 Mar; 175(5):458-63. PubMed ID: 17158282
[TBL] [Abstract][Full Text] [Related]
19. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
20. Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD.
Mendes ES; Campos MA; Wanner A
Chest; 2006 Apr; 129(4):893-8. PubMed ID: 16608935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
